Doctor's Digest
Because You Need More Than Just Clinical Information
Doctor's Digest is an in-depth, single-topic publication that features medical current events and noted experts offering practical tips on how doctors can get the most out of their professional lives.
The current issue focuses on "Personal and Professional Growth," and includes healthcare news articles on flextime arrangements, lifelong learning, and new practice options.
Download the free Adobe® Reader® plug-in.
Except as otherwise noted, content is strictly controlled by the publishers of Doctor's Digest
January — February 2007: Evidence-based Medicine
July — August 2006: Patient-Physician Communications
- Introduction
- Chapter 1 - Impact of Communications on Health Outcomes
- Chapter 2 - Patient Communication: From Check-in to Check-out
- Chapter 3 - Breaking Down Barriers to Effective Communication
- Chapter 4 - Crisis Situations Call For Clear Communication
- Chapter 5 - Digital Tools Can Enhance Flow of Information
- Appendix - Additional Resources
January — February 2006: Technology in Practice
- Introduction
- Chapter 1 - Making the Case for Electronic Health Records
- Chapter 2 - Factors to Consider When Selecting a System
- Chapter 3 - Making the Transition: Rethinking Workflows
- Chapter 4 - Access Data From Anywhere With Handheld Devices
- Chapter 5 - Internet Seen Transforming Research, Communications
- Appendix - Additional Resources
Dispensing errors have been reported between TOPAMAX® (topiramate) Tablets and TOPROL-XL® (metoprolol succinate) extended-release Tablets.
Please be sure to check your tablets to ensure you are taking the right medicine.
*TOPROL-XL is a registered trademark of the AstraZeneca group of companies.
TOPAMAX Tablets and TOPAMAX Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX in the acute treatment of migraine headache has not been studied.
TOPAMAX is contraindicated in patients with a history of hypersensitivity to any component of this product.
IMPORTANT SAFETY INFORMATION
TOPAMAX has been associated with serious adverse events, including:
- Hyperchloremic, non-anion gap metabolic acidosis - lowering of bicarbonate levels in the blood. Measurement of baseline and periodic serum bicarbonate is recommended.
- Acute myopia and secondary angle-closure glaucoma - patients should be cautioned to seek medical attention if they experience blurred vision or ocular pain.
- Oligohidrosis and hyperthermia - decreased sweating and increased body temperature, especially in hot weather. The majority of reports have been in children.
- Cognitive/psychiatric side effects including cognitive dysfunction, psychiatric/behavioral disturbances, including suicidal thoughts or behavior, and somnolence and fatigue.
Most common adverse events associated with TOPAMAX 100 mg vs placebo were: paresthesia, 51% vs 6%; anorexia,* 15% vs 6%; fatigue, 15% vs 11%; nausea, 13% vs 8%; diarrhea, 11% vs 4%; weight decrease, 9% vs 1%; taste alteration, 8% vs 1%.
The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX.
Patients should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation.
*Anorexia is defined as loss of appetite
Please see full U.S. Prescribing Information
